Skip to main content
  • Book
  • © 2008

Aromatase Inhibitors

Birkhäuser
  • First comprehensive overview on the different aromatase inhibitors

  • Includes preclinical and clinical studies

  • Gives outlook on future uses of aromatase inhibitors

  • International authorship

Part of the book series: Milestones in Drug Therapy (MDT)

Buying options

eBook USD 129.00
Price excludes VAT (USA)
  • ISBN: 978-3-7643-8693-1
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book USD 169.00
Price excludes VAT (USA)

This is a preview of subscription content, access via your institution.

Table of contents (9 chapters)

  1. Front Matter

    Pages I-X
  2. Clinical pharmacology of aromatase inhibitors

    • Jürgen Geisler, Per Eystein Lønning
    Pages 45-52
  3. Clinical studies with exemestane

    • Robert J. Paridaens
    Pages 53-68
  4. Clinical studies with letrozole

    • J. Michael Dixon
    Pages 69-100
  5. Clinical studies with anastrozole

    • Anthony Howell, Alan Wakeling
    Pages 101-125
  6. Lessons from the ArKO mouse

    • Evan R. Simpson, Margaret E. Jones, Colin D. Clyne
    Pages 147-163
  7. Back Matter

    Pages 185-192

About this book

Many breast tumours are dependent upon oestrogen for their development and continued growth. Over the last 25 years hormone therapy has progressed from the irreversible destruction of endocrine glands to the use of drugs that reversibly suppress oestrogen synthesis or action. The inhibition of oestrogen synthesis is most readily achieved by inhibiting the final step in the pathway of oestrogen biosynthesis, the reaction which transforms androgens into oestrogens by creating an aromatic ring in the steroid molecule (hence the enzyme's trivial name, aromatase).
Whereas the first aromatase inhibitors to be used therapeutically could be shown to produce drug-induced inhibition of the enzyme and therapeutic benefits in patients with breast cancer, they were not particularly potent and lacked specificity. However, second-generation drugs were developed and most recently third-generation inhibitors have evolved which possess remarkable specificity and potency. Initial results from clinical trials suggest that these agents will become the cornerstones of future endocrine therapy.

Keywords

  • Brustkrebs
  • Drogen
  • Treatment
  • biosynthesis
  • breast cancer
  • cancer
  • clinical trial
  • development
  • enzyme
  • enzymes
  • hormone therapy
  • hormones
  • pharmacology
  • research
  • tumor

Editors and Affiliations

  • Global Discovery, AstraZeneca, Macclesfield Cheshire, UK

    Barrington J. A. Furr

Bibliographic Information

Buying options

eBook USD 129.00
Price excludes VAT (USA)
  • ISBN: 978-3-7643-8693-1
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book USD 169.00
Price excludes VAT (USA)